Shuttle End Period Cash Flow vs Capital Expenditures Analysis

SHPH Stock

USD 0.93 0.08 9.41%

Shuttle Pharmaceuticals financial indicator trend analysis is much more than just breaking down Shuttle Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Shuttle Pharmaceuticals is a good investment. Please check the relationship between Shuttle Pharmaceuticals End Period Cash Flow and its Capital Expenditures accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Shuttle Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Shuttle Stock please use our How to Invest in Shuttle Pharmaceuticals guide.

End Period Cash Flow vs Capital Expenditures

End Period Cash Flow vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Shuttle Pharmaceuticals End Period Cash Flow account and Capital Expenditures. At this time, the significance of the direction appears to have no relationship.

The correlation between Shuttle Pharmaceuticals' End Period Cash Flow and Capital Expenditures is 0.08. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Shuttle Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Shuttle Pharmaceuticals' End Period Cash Flow and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Shuttle Pharmaceuticals are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of End Period Cash Flow i.e., Shuttle Pharmaceuticals' End Period Cash Flow and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

0.08

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

End Period Cash Flow

Capital Expenditures

Capital Expenditures are funds used by Shuttle Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Shuttle Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most indicators from Shuttle Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Shuttle Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Shuttle Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Shuttle Stock please use our How to Invest in Shuttle Pharmaceuticals guide.The current Selling General Administrative is estimated to decrease to about 930.2 K. The Shuttle Pharmaceuticals' current Issuance Of Capital Stock is estimated to increase to about (19.9 K)

	2022	2023	2024	2025 (projected)
Total Operating Expenses	2.6M	5.9M	6.8M	3.6M
Cost Of Revenue	66.8K	6.8K	6.1K	5.8K

Total Operating Expenses Cost Of Revenue

Shuttle Pharmaceuticals fundamental ratios Correlations

	Total Current Liabilities	Net Tangible Assets	Net Receivables	Total Current Assets	Common Stock	Property Plant Equipment	Retained Earnings	Other Current Liab	Accounts Payable	Other Assets	Other Current Assets	Other Stockholder Equity	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Total Liab
Total Current Liabilities		0.06	0.31	0.25	-0.77	0.8	-0.4	0.84	0.93	-0.17	-0.96	0.35	0.23	0.34	0.22	0.04	0.46	-0.17	0.2	0.04	-0.17	0.24	-0.12	0.2	0.1	-0.18
Net Tangible Assets	0.06		-0.48	0.95	-0.37	-0.14	-0.87	-0.34	-0.06	-0.67	-0.17	0.9	0.93	0.65	0.91	0.49	0.77	-0.71	0.78	0.48	-0.67	0.92	-0.55	0.95	0.66	-0.85
Net Receivables	0.31	-0.48		-0.4	0.01	0.72	0.29	0.76	0.27	0.25	-0.35	-0.33	-0.38	-0.35	-0.38	-0.13	-0.48	0.31	-0.34	-0.12	0.25	-0.39	0.24	-0.37	-0.2	0.34
Total Current Assets	0.25	0.95	-0.4		-0.51	0.01	-0.83	-0.17	0.1	-0.58	-0.32	0.95	0.98	0.55	0.98	0.3	0.82	-0.86	0.91	0.29	-0.58	0.98	-0.53	0.96	0.47	-0.95
Common Stock	-0.77	-0.37	0.01	-0.51		-0.37	0.55	-0.44	-0.58	0.3	0.68	-0.53	-0.47	-0.41	-0.46	-0.17	-0.55	0.37	-0.41	-0.16	0.3	-0.47	0.29	-0.46	-0.25	0.41
Property Plant Equipment	0.8	-0.14	0.72	0.01	-0.37		-0.19	0.93	0.82	-0.08	-0.87	0.11	0.01	0.12	0.0	-0.03	0.15	0.01	0.01	-0.04	-0.08	0.01	0.01	-0.01	0.01	0.0
Retained Earnings	-0.4	-0.87	0.29	-0.83	0.55	-0.19		-0.02	-0.31	0.82	0.51	-0.85	-0.78	-0.87	-0.74	-0.64	-0.81	0.45	-0.56	-0.64	0.82	-0.77	0.39	-0.83	-0.82	0.66
Other Current Liab	0.84	-0.34	0.76	-0.17	-0.44	0.93	-0.02		0.8	0.09	-0.82	-0.06	-0.17	-0.01	-0.18	-0.09	-0.03	0.16	-0.16	-0.08	0.09	-0.17	0.09	-0.18	-0.1	0.18
Accounts Payable	0.93	-0.06	0.27	0.1	-0.58	0.82	-0.31	0.8		-0.12	-0.94	0.21	0.08	0.36	0.07	0.01	0.44	-0.01	0.05	0.0	-0.12	0.09	-0.09	0.06	0.06	-0.01
Other Assets	-0.17	-0.67	0.25	-0.58	0.3	-0.08	0.82	0.09	-0.12		0.29	-0.49	-0.45	-0.62	-0.42	-0.42	-0.45	0.2	-0.31	-0.42	1.0	-0.45	0.15	-0.48	-0.78	0.5
Other Current Assets	-0.96	-0.17	-0.35	-0.32	0.68	-0.87	0.51	-0.82	-0.94	0.29		-0.41	-0.29	-0.45	-0.27	-0.14	-0.52	0.18	-0.22	-0.14	0.29	-0.3	0.2	-0.28	-0.23	0.23
Other Stockholder Equity	0.35	0.9	-0.33	0.95	-0.53	0.11	-0.85	-0.06	0.21	-0.49	-0.41		0.98	0.66	0.96	0.43	0.9	-0.79	0.85	0.42	-0.49	0.97	-0.42	0.97	0.47	-0.86
Total Assets	0.23	0.93	-0.38	0.98	-0.47	0.01	-0.78	-0.17	0.08	-0.45	-0.29	0.98		0.54	1.0	0.32	0.84	-0.88	0.92	0.31	-0.45	1.0	-0.51	0.98	0.4	-0.93
Short Long Term Debt Total	0.34	0.65	-0.35	0.55	-0.41	0.12	-0.87	-0.01	0.36	-0.62	-0.45	0.66	0.54		0.49	0.83	0.78	-0.11	0.22	0.82	-0.62	0.53	-0.29	0.63	0.83	-0.28
Total Stockholder Equity	0.22	0.91	-0.38	0.98	-0.46	0.0	-0.74	-0.18	0.07	-0.42	-0.27	0.96	1.0	0.49		0.26	0.82	-0.91	0.94	0.25	-0.42	1.0	-0.51	0.97	0.35	-0.94
Property Plant And Equipment Net	0.04	0.49	-0.13	0.3	-0.17	-0.03	-0.64	-0.09	0.01	-0.42	-0.14	0.43	0.32	0.83	0.26		0.39	0.16	-0.07	1.0	-0.42	0.29	-0.25	0.47	0.87	-0.01
Current Deferred Revenue	0.46	0.77	-0.48	0.82	-0.55	0.15	-0.81	-0.03	0.44	-0.45	-0.52	0.9	0.84	0.78	0.82	0.39		-0.64	0.7	0.38	-0.45	0.85	-0.39	0.83	0.43	-0.69
Net Debt	-0.17	-0.71	0.31	-0.86	0.37	0.01	0.45	0.16	-0.01	0.2	0.18	-0.79	-0.88	-0.11	-0.91	0.16	-0.64		-0.99	0.17	0.2	-0.89	0.4	-0.79	0.05	0.95
Cash	0.2	0.78	-0.34	0.91	-0.41	0.01	-0.56	-0.16	0.05	-0.31	-0.22	0.85	0.92	0.22	0.94	-0.07	0.7	-0.99		-0.08	-0.31	0.93	-0.42	0.84	0.07	-0.98
Non Current Assets Total	0.04	0.48	-0.12	0.29	-0.16	-0.04	-0.64	-0.08	0.0	-0.42	-0.14	0.42	0.31	0.82	0.25	1.0	0.38	0.17	-0.08		-0.42	0.28	-0.25	0.46	0.87	0.0
Non Currrent Assets Other	-0.17	-0.67	0.25	-0.58	0.3	-0.08	0.82	0.09	-0.12	1.0	0.29	-0.49	-0.45	-0.62	-0.42	-0.42	-0.45	0.2	-0.31	-0.42		-0.45	0.15	-0.48	-0.78	0.5
Cash And Short Term Investments	0.24	0.92	-0.39	0.98	-0.47	0.01	-0.77	-0.17	0.09	-0.45	-0.3	0.97	1.0	0.53	1.0	0.29	0.85	-0.89	0.93	0.28	-0.45		-0.51	0.98	0.38	-0.93
Common Stock Shares Outstanding	-0.12	-0.55	0.24	-0.53	0.29	0.01	0.39	0.09	-0.09	0.15	0.2	-0.42	-0.51	-0.29	-0.51	-0.25	-0.39	0.4	-0.42	-0.25	0.15	-0.51		-0.58	-0.36	0.41
Non Current Liabilities Total	0.2	0.95	-0.37	0.96	-0.46	-0.01	-0.83	-0.18	0.06	-0.48	-0.28	0.97	0.98	0.63	0.97	0.47	0.83	-0.79	0.84	0.46	-0.48	0.98	-0.58		0.53	-0.86
Capital Lease Obligations	0.1	0.66	-0.2	0.47	-0.25	0.01	-0.82	-0.1	0.06	-0.78	-0.23	0.47	0.4	0.83	0.35	0.87	0.43	0.05	0.07	0.87	-0.78	0.38	-0.36	0.53		-0.23
Total Liab	-0.18	-0.85	0.34	-0.95	0.41	0.0	0.66	0.18	-0.01	0.5	0.23	-0.86	-0.93	-0.28	-0.94	-0.01	-0.69	0.95	-0.98	0.0	0.5	-0.93	0.41	-0.86	-0.23

Click cells to compare fundamentals

Shuttle Pharmaceuticals Account Relationship Matchups

Currently Active Assets on Macroaxis

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin
ADA	Cardano
XRP	XRP

When determining whether Shuttle Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Shuttle Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Shuttle Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Shuttle Pharmaceuticals Stock:

How To Invest In Shuttle

Details

Is Shuttle Stock a good investment?

Details

What is Shuttle Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Shuttle Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Shuttle Stock please use our How to Invest in Shuttle Pharmaceuticals guide.

You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Shuttle Pharmaceuticals. If investors know Shuttle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Shuttle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.25)

Return On Assets

(0.62)

Return On Equity

(1.86)

The market value of Shuttle Pharmaceuticals is measured differently than its book value, which is the value of Shuttle that is recorded on the company's balance sheet. Investors also form their own opinion of Shuttle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Shuttle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Shuttle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Shuttle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Shuttle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Shuttle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Shuttle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Shuttle End Period Cash Flow vs Capital Expenditures Analysis

End Period Cash Flow vs Capital Expenditures

End Period Cash Flow vs Capital Expenditures Correlation Analysis

Correlation Coefficient

End Period Cash Flow

Capital Expenditures

Shuttle Pharmaceuticals fundamental ratios Correlations

Shuttle Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Currrent Assets Other	+ 1.0	Other Assets
Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Assets	+ 0.98	Total Current Assets

Cash	- 0.99	Net Debt
Total Liab	- 0.98	Cash
Other Current Assets	- 0.96	Total Current Liabilities
Total Liab	- 0.95	Total Current Assets
Total Liab	- 0.94	Total Stockholder Equity
Other Current Assets	- 0.94	Accounts Payable